Get started
GSK plcGSK plcGSK plc

GSK plc

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsBondsETFs

Live chart


Full chart

Key facts today


On October 20, 2025, GSK plc bought 4,643,500 shares, raising its treasury shares to 252,108,344, which is 6.20% of total voting rights.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪87.71 B‬ USD
Dividend yield (indicated)
3.94%
Price to earnings Ratio (TTM)
19.58
Basic EPS (TTM)
1.15 USD
Net income (FY)
‪3.22 B‬ USD
Revenue (FY)
‪39.25 B‬ USD
Shares float
‪3.88 B‬
Beta (1Y)
1.09

Employees


Employees (FY)
‪68.63 K‬
Change (1Y)
‪−1.58 K‬ −2.25%
Revenue / Employee (1Y)
‪571.98 K‬ USD
Net income / Employee (1Y)
‪46.94 K‬ USD

About GSK plc


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Emma N. Walmsley
Website
gsk.com
Headquarters
London
ISIN
GB00BN7SWP63
FIGI
BBG000CVPWL6
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Check out other big names from the same industry as GLAXF.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


83GI
GlaxoSmithKline Capital Plc 5.25% 10-APR-2042
Yield to maturity
5.79%
Maturity date
Apr 10, 2042
17RI
GlaxoSmithKline Capital Plc 4.25% 18-DEC-2045
Yield to maturity
5.61%
Maturity date
Dec 18, 2045
71ZC
GlaxoSmithKline Capital Plc 6.375% 09-MAR-2039
Yield to maturity
5.51%
Maturity date
Mar 9, 2039
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043
Yield to maturity
5.12%
Maturity date
Mar 18, 2043
XS217060907
GlaxoSmithKline Capital Plc 1.625% 12-MAY-2035
Yield to maturity
5.10%
Maturity date
May 12, 2035
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038
Yield to maturity
4.87%
Maturity date
May 15, 2038
72WI
GlaxoSmithKline Capital, Inc. 5.375% 15-APR-2034
Yield to maturity
4.67%
Maturity date
Apr 15, 2034
AG99
GlaxoSmithKline Capital Plc 5.25% 19-DEC-2033
Yield to maturity
4.60%
Maturity date
Dec 19, 2033
GSK6023693
GlaxoSmithKline Capital, Inc. 4.875% 15-APR-2035
Yield to maturity
4.58%
Maturity date
Apr 15, 2035
XS217060184
GlaxoSmithKline Capital Plc 1.25% 12-OCT-2028
Yield to maturity
4.08%
Maturity date
Oct 12, 2028
GSK6023695
GlaxoSmithKline Capital, Inc. 4.5% 15-APR-2030
Yield to maturity
4.00%
Maturity date
Apr 15, 2030

See all GLAXF bonds 

ETFs


VXUS
Vanguard Total International Stock ETF
Weight
0.23%
Market value
‪1.26 B‬
USD
VEA
Vanguard FTSE Developed Markets ETF
Weight
0.32%
Market value
‪804.69 M‬
USD
IEFA
iShares Core MSCI EAFE ETF
Weight
0.39%
Market value
‪606.52 M‬
USD
ISF
iShares Core FTSE 100 UCITS ETF GBP (Dist)
Weight
2.87%
Market value
‪508.35 M‬
USD
ISFD
iShares PLC - iShares Core FTSE 100 UCITS ETF Accum Hedged USD
Weight
2.87%
Market value
‪508.35 M‬
USD
EFA
iShares MSCI EAFE ETF
Weight
0.45%
Market value
‪307.30 M‬
USD
EFV
iShares MSCI EAFE Value ETF
Weight
0.91%
Market value
‪241.62 M‬
USD
VUKG
Vanguard Funds PLC - Vanguard FTSE 100 UCITS ETF AccumGBP
Weight
2.80%
Market value
‪217.05 M‬
USD
VUKE
Vanguard FTSE 100 UCITS ETF
Weight
2.80%
Market value
‪217.05 M‬
USD
VGK
Vanguard FTSE Europe ETF
Weight
0.60%
Market value
‪213.19 M‬
USD
VEU
Vanguard FTSE All-World ex-US Index Fund
Weight
0.25%
Market value
‪187.31 M‬
USD

Explore more ETFs 

Sparks


Curated watchlists where GLAXF is featured.

See all sparks 

Frequently Asked Questions


The current price of GLAXF is 21.70 USD — it has decreased by −0.44% in the past 24 hours. Watch GSK plc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange GSK plc stocks are traded under the ticker GLAXF.
GLAXF stock has fallen by −0.14% compared to the previous week, the month change is a 9.78% rise, over the last year GSK plc has showed a 5.61% increase.
We've gathered analysts' opinions on GSK plc future price: according to them, GLAXF price has a max estimate of 33.83 USD and a min estimate of 15.03 USD. Watch GLAXF chart and read a more detailed GSK plc stock forecast: see what analysts think of GSK plc and suggest that you do with its stocks.
GLAXF reached its all-time high on Feb 14, 2007 with the price of 37.37 USD, and its all-time low was 13.48 USD and was reached on Sep 26, 2022. View more price dynamics on GLAXF chart.
See other stocks reaching their highest and lowest prices.
GLAXF stock is 4.81% volatile and has beta coefficient of 1.09. Track GSK plc stock price on the chart and check out the list of the most volatile stocks — is GSK plc there?
Today GSK plc has the market capitalization of ‪87.72 B‬, it has increased by 1.05% over the last week.
Yes, you can track GSK plc financials in yearly and quarterly reports right on TradingView.
GSK plc is going to release the next earnings report on Oct 29, 2025. Keep track of upcoming events with our Earnings Calendar.
GLAXF earnings for the last quarter are 0.64 USD per share, whereas the estimation was 0.60 USD resulting in a 7.25% surprise. The estimated earnings for the next quarter are 0.63 USD per share. See more details about GSK plc earnings.
GSK plc revenue for the last quarter amounts to ‪10.96 B‬ USD, despite the estimated figure of ‪10.68 B‬ USD. In the next quarter, revenue is expected to reach ‪11.04 B‬ USD.
GLAXF net income for the last quarter is ‪1.98 B‬ USD, while the quarter before that showed ‪2.10 B‬ USD of net income which accounts for −5.55% change. Track more GSK plc financial stats to get the full picture.
GSK plc dividend yield was 4.53% in 2024, and payout ratio reached 96.58%. The year before the numbers were 4.00% and 47.69% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Oct 21, 2025, the company has ‪68.63 K‬ employees. See our rating of the largest employees — is GSK plc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GSK plc EBITDA is ‪12.66 B‬ USD, and current EBITDA margin is 26.18%. See more stats in GSK plc financial statements.
Like other stocks, GLAXF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GSK plc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GSK plc technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GSK plc stock shows the buy signal. See more of GSK plc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.